Opendata, web and dolomites

NOC

Nerve-on-Chips

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOC project word cloud

Explore the words cloud of the NOC project. It provides you a very rough idea of what is the project "NOC" about.

burden    reconstructed    prevent    memories    feasibility    trillion    absence    latter    nd    turn    patent    chain    technological    reduce    visualization    efficiency    policy    functions    grow    2020    life    drugs    individual       biotech    agencies    3d    million    devastating    ultimately    few    predicting    coming    care    networks    biopharmaceutical    animal    competitiveness    readouts    noc    independence    organoids    alzheimer    ip    2d    micron    nerve    15    time    patented    worth    biological    subunits    people    conventional    health    human    incidence    patients    organ    relatives    microfluidic    clients    competitors    individuals    provides       market    ooc    society    validating    financial    vitro    licenses    start    assessing    generate    turnover    microbrain    types    models    culture    dimensional    suffer    advantages    tri    worldwide    economic    reconstitution    solutions    drug    chips    shape    neuron    physiological    innovative    simulate    expectancy    subcategory    cureor    improvement    65    compatibility    lose    neurodegenerative    startup    disease    tissues    supply    clinical    biology    purchase    function    diseases    total    2014    founded    mbbt    lives    share   

Project "NOC" data sheet

The following table provides information about the project.

Coordinator
MICROBRAIN BIOTECH 

Organization address
address: 46 RUE CARDINET
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://microbrainbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROBRAIN BIOTECH FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More